Orion OYJ (OTCMKTS:ORINY) Shares Gap Up – Still a Buy?

Orion OYJ Unsponsored ADR (OTCMKTS:ORINY)’s stock price gapped up prior to trading on Monday . The stock had previously closed at $35.28, but opened at $36.8425. Orion OYJ shares last traded at $36.8425, with a volume of 100 shares traded.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on ORINY shares. Nordea Equity Research raised Orion OYJ from a “hold” rating to a “buy” rating in a research note on Monday, October 6th. Zacks Research cut Orion OYJ from a “strong-buy” rating to a “hold” rating in a report on Monday, September 8th. One investment analyst has rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy”.

Orion OYJ Price Performance

The company has a quick ratio of 1.19, a current ratio of 1.99 and a debt-to-equity ratio of 0.13. The firm’s fifty day moving average price is $35.09 and its 200-day moving average price is $37.47. The stock has a market cap of $10.40 billion, a P/E ratio of 29.71 and a beta of 0.06.

Orion OYJ (OTCMKTS:ORINY) last announced its quarterly earnings results on Tuesday, October 28th. The company reported $0.40 earnings per share (EPS) for the quarter. Orion OYJ had a net margin of 19.33% and a return on equity of 31.36%. The business had revenue of $494.69 million for the quarter. Analysts forecast that Orion OYJ Unsponsored ADR will post 1.18 earnings per share for the current year.

Orion OYJ Dividend Announcement

The firm also recently declared a dividend, which was paid on Friday, November 7th. Investors of record on Friday, October 17th were issued a dividend of $0.2418 per share. This represents a yield of 127.0%. The ex-dividend date was Thursday, October 16th. Orion OYJ’s payout ratio is currently 26.61%.

Orion OYJ Company Profile

Orion Corporation (Orion Oyj) is a Finland-based pharmaceutical company engaged in the research, development, manufacture and marketing of human and veterinary medicines as well as diagnostic tests. The company’s core therapeutic areas include central nervous system disorders, oncology and respiratory diseases, and it offers both proprietary and generic products. Orion’s product range spans from small-molecule drugs and active pharmaceutical ingredients to radiodiagnostic imaging agents and line extensions developed through in-house research.

Since its founding in 1917 in Helsinki, Orion has grown into an integrated pharmaceuticals business with state-of-the-art manufacturing facilities in Finland and France.